Original Article
ISSN (Online): 2582-7472

ShodhKosh: Journal of Visual and Performing Arts
June 2024 5(6), 1497–1505

ADVANCES IN MELANOMA DETECTION: A COMPREHENSIVE REVIEW OF EMERGING TECHNOLOGIES AND TECHNIQUES

Vinay S. Nalawade [1], Dr. Shailesh Kumar [2] Dr. Shrinivas T. Shirkande

[1] Research Scholar, Department of Computer Engineering, Shri Jagdishprasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India
[2] Associate Professor, Department of Computer Engineering, Shri Jagdishprasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India
[3] Principal & Associate Professor, S B Patil College of Engineering, Indapur, Pune, Maharashtra, India

Corresponding Author
Vinay S. Nalawade,
vinaynalawade2007@gmail.com

DOI
10.29121/shodhkosh.v5.i6.2024.4824

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ABSTRACT

Melanoma detection has come a long way, mostly thanks to breakthroughs in image technologies and machine learning techniques that aim to make diagnoses more accurate and improve patient results. Traditional techniques like dermoscopy and biopsy are still very important. However, newer technologies like multispectral images and computer-assisted analysis have made it much easier to tell the difference between normal and cancerous tumours early on. This review talks about how melanoma detection tools have changed over time and where they are now. It also talks about how artificial intelligence (AI) is being used in dermatology. Some new developments in high-resolution imaging, like confocal microscopy and optical coherence tomography, offer non-invasive options for deeper tissue analysis and real-time identification of cancerous cells, which can be very important for starting treatment early. Also, improvements in teledermatology have made it easier to do screenings from afar, making it easier for more people to get expert care and second views, which is especially helpful in areas that don't have enough resources. Melanoma identification has been changed forever by the use of deep learning models that can look at pictures of skin lesions with the same level of accuracy as doctors. These AI systems are trained on very large datasets and are being used more and more to help doctors make decisions, which could help cut down on medical mistakes and bias. Not only that, but AI-powered tools also show a lot of promise for keeping track of how lesions change over time, which is an important part of watching for melanoma. Also, genetic markers and biomarkers have become very useful for finding people who are at risk, which allows for proactive control and personalised treatment plans.

Keywords: Melanoma Detection, Artificial Intelligence, Imaging Technologies, Deep Learning, Biomarkers

1. INTRODUCTION

Melanoma, the most deadly type of skin cancer, is becoming more common around the world. This makes improving screening methods an important area for study and development. Finding melanoma early can greatly increase the chance of surviving, which shows how important it is to have good screening tools and testing methods. Visual inspection and dermoscopy, which are old methods, have been the main ways that melanoma has been diagnosed. But these methods depend a lot on the clinician's knowledge and can be subjective, which can make the accuracy of the diagnosis vary. To get around these problems, a lot of progress has been made in technology in the last few years that is meant to make melanoma diagnosis more accurate and faster. A breakthrough that looks especially hopeful is the use of artificial intelligence (AI) in dermatology [1]. This has completely changed the field by creating tools that can analyse skin diseases as accurately as trained doctors. Deep learning techniques are used by AI-based diagnosis systems to look at and process thousands of pictures. These systems learn to find small trends that could mean someone has cancer. These systems are trained on a variety of datasets that include different skin types and disease looks. This makes it easier for them to work correctly across different groups [2].



Figure 1 Representation of different types of skin Melanoma cancer

Melanoma diagnosis has also come a long way thanks to the growth of teledermatology. Teledermatology has made it easier for people to get expert care, especially in places that don't have enough of it, and it has also made skin cancer screening programs more effective. This method not only speeds up the diagnosis process, but it also improves patient follow-up and ongoing tracking, which is very important for people who are very likely to get melanoma. Wearable technologies that track changes in skin tumours over time are also being made [3]. This could allow people who are at a high risk of getting melanoma to be continuously and non-invasively watched. Furthermore, finding genetic markers and analysing biomarkers are giving us more information about personal risk factors and are paving the way for more personalised ways to find and treat melanoma. These signs can help find people whose genes make them more likely to get melanoma, so they can be watched and treated earlier. New developments in multispectral imaging give us new ways to look at skin lesions. These new methods use various bands of light to catch special features of skin lesions that we might not be able to see with the naked eye. As [4] these technologies keep getting better, they should be able to work better with clinical processes, making doctors' jobs easier and making sure that melanoma is found more accurately and earlier.

Table 1 Overview of Various Methods used in Melanoma Detection and its Comparison

Method	Non-Invasiveness	Cost	Reliability in Early Detection
Visual Examination [3]	High	Low	Moderate
Confocal Microscopy [5]	High	High	Very High
Optical Coherence Tomography (OCT) [6]	High	High	High
Multispectral Imaging [7]	High	High	High
Total Body Photography [8]	High	Moderate	Moderate
AI with Dermoscopic Images [9]	High	Moderate	Very High
AI with Confocal Microscopy [10]	High	High	Very High
Genetic Testing [11]	Low	Very High	Low
Biochemical Markers [12]	Low	Moderate	Moderate
Teledermatology [13]	High	Moderate	High
Wearable Monitoring Devices [14]	High	Moderate	Moderate

2. TRADITIONAL METHODS OF MELANOMA DETECTION

Melanoma can be found using traditional methods like dermoscopy, eye examination, and sample followed by histopathological examination. These methods have been widely used for decades and are the basis of skin cancer identification.

1) Visual Examination and Dermoscopy

Dermatologists who are trained to look at the skin are the first line of defence against melanoma. Moles and other skin growths are checked out, paying special attention to changes in their size, shape, colour, and feel. Although this method is easy to use and doesn't involve any harm, the accuracy of the evaluation can vary depending on the clinician's experience and skill. A mobile tool called a dermatoscope is often used by doctors to improve the accuracy of eye exams [4]. This is called dermoscopy. With this device's magnification and lighting, skin tumours can be looked at more closely, showing patterns and structures that can't be seen with the naked eye. Dermoscopy makes it much easier to tell if someone has melanoma and lessens the number of tests that are done on minor growths.

2) Biopsy and Histopathological Examination

When a growth is thought to be cancerous, a biopsy is done to get a piece of tissue for further testing. This is the most accurate way to diagnose cancer. A suspicious tumour is either cut out in whole or in pieces, and this is then sent to a pathology lab to be looked at under a microscope using histopathology. Pathologists can look at the molecular features of the tissue with this method, which gives them clear proof of the presence of cancer cells and the type of melanoma [5]. The histopathological study is very exact, but it requires cutting the skin very deeply, which can be painful and sometimes cause an illness.

3. ADVANCED IMAGING TECHNOLOGIES

1) Confocal Microscopy

Confocal microscopy is a new type of image technology that is becoming more and more useful in dermatology, especially for checking for skin cancers like melanoma without cutting the skin. A laser is used in this method to scan skin tissues and take detailed pictures of cells at different levels. The results are high-resolution, real-time pictures that look like pictures taken from biopsies [6], [7]. Focussing a single colour of light on a small area of skin and measuring the light that bounces back from the tissue is how confocal imaging works.

Confocal microscopy is most useful for finding melanoma because it can tell the difference between harmless and cancerous skin growths without a physical test. It works especially well for looking at borderline tumours that are hard to assess with other tools. Confocal imaging, which gives a view at the cellular level, can help find the abnormal structure and disorganisation that are common in melanoma cells, which can help with early discovery. This method lets doctors keep an eye on worrisome sores over time, which greatly cuts down on the need for biopsies and the pain they cause patients. There are a lot of good things about confocal imaging [8], [9].

2) Optical Coherence Tomography (OCT)

Optical Coherence Tomography (OCT) [10] is another advanced screening method that makes it easier to find cancer. OCT works in a way that is similar to ultrasound imaging, but it uses light waves instead of sound waves. By measuring the echo time delay and amount of backscattered light from inside tissue structures, it can make cross-sectional pictures of the skin. This method can get pictures up to about 2 mm below the skin's surface and can resolve details at the micron level. It can also go deeper into the skin than confocal imaging. Compared to other ways of finding cancer, OCT has a number of benefits. Compared to dermoscopy and an eye test, OCT gives a more objective evaluation by creating detailed pictures below the skin's surface that can show structural issues connected to cancerous growths. It gets around the subjective nature of human sight and relies less on direct visual cues, which can be wrong sometimes. OCT is also non-invasive, which means that tissue does not have to be removed. This means that the risks and pain of biopsies are not present.

With OCT [11], It able see layers of skin that you can't see with the naked eye or with surface imaging methods. This means that melanoma can be found earlier, even before it shows up on the surface. Because of this, it is a great tool for keeping an eye on patients who are at high risk, giving you a safety net that can help you act faster and improve the patient's result [12], [13]. The OCT's quick ability to produce detailed pictures also makes it easier to map out the edges of a tumour more accurately, which is important for planning surgery cuts and making sure that all cancerous cells are removed.

TABLE 2 SUMMARIZING THE KEY ASPECTS OF THE ADVANCED IMAGING TECHNOLOGIES

Parameter	Confocal Microscopy [14]	Optical Coherence Tomography (OCT) [15]	Multispectral Imaging (MSI) [16]
Applications	Differentiates benign from malignant lesions; useful for examining borderline lesions.	Visualizes subsurface skin structures, aiding in early detection and detailed analysis of lesions.	Enhances lesion analysis by providing spectral profiles that help differentiate between benign and malignant lesions.
Advantages	Non-invasive, reduces the need for biopsies; provides real-time, cellular-level imaging.	Non-invasive; deeper tissue penetration than confocal microscopy; provides detailed structural images.	Non-invasive; capable of detecting subtle pigmentation and vascular changes; supports automated screening.
Challenges	Requires skilled interpretation; limited penetration depth compared to OCT.	Requires interpretation of complex images; may miss very superficial lesions due to deeper focus.	Requires advanced imaging equipment and analysis software; may require calibration for accurate results.

This table 2 quickly compares the three advanced imaging technologies, showing how they work, what they can be used for, their benefits, and how they affect identification and patient results when finding melanoma.

4. ARTIFICIAL INTELLIGENCE IN MELANOMA DETECTION

1) Development of AI Models for Skin Cancer Screening

A big step forward in dermatological detection is the creation of artificial intelligence (AI) models for skin cancer screening. A lot of dermatoscopic pictures have been used to teach AI, especially deep learning models like convolutional neural networks (CNNs), to recognise skin tumours and decide whether they are normal or cancerous. These models are made to look at visual patterns and find problems with a level of accuracy that is often the same as or better than what humans can do [17]. The AI is trained by showing it thousands of labelled pictures of different skin conditions. This teaches it to spot small changes in shape, colour, texture, and border flaws that could be signs of melanoma. To make sure the model is stable and improve its ability to generalise, researchers often add pictures taken in different lighting situations and from different angles to this training data. This in-depth training is very important because skin lesions can look very different on different people, depending on things like skin tone and where the lesion is located. Improvements in computing power and methods have also led to better AI skills. These [18] improvements allow for real-time research and diagnosis.



Figure 2 Overview of AI based detection Model

2) Performance of AI Systems Compared to Dermatologists

A lot of research has been done on how well AI systems can find melanoma. Many studies have compared their accuracy to that of trained doctors using diagnosis tests. In general, AI systems have shown a high level of accuracy, often matching or even beating that of human experts. Several standard studies have shown that AI systems are better at finding melanoma than humans. This is very important because melanoma can be fatal if it is not found early [19].

The best thing about these AI systems is that they can look at every picture with the same level of accuracy and consistency, even if they are tired or have different amounts of experience and training, which can affect a person's judgement [20]. Also, AI can look at pictures and make diagnoses a lot faster than human doctors can. It might be able to look at thousands of pictures in the time it takes a dermatologist to look at a few dozen. However, this speed does not mean less accuracy. In fact, using AI in testing processes can help lower the number of mistakes and missed cases of melanoma.

TABLE 3 COMPARISON OF AI AND DERMATOLOGIST PERFORMANCE IN MELANOMA DETECTION

Method Used	AI Sensitivity (%)	AI Specificity (%)	Dermatologist Sensitivity (%)	Dermatologist Specificity (%)
CNN with Dermoscopic Images [15]	95	85	86	71
AI with Confocal Microscopy [17]	91	89	83	75
Hybrid AI (CNN + OCT) [18]	94	92	90	80

This table 3 shows how AI systems that are combined with different image technologies perform better than standard dermatology exams in terms of both sensitivity and specificity. This shows how AI can improve the accuracy of melanoma diagnosis.



Figure 3 Comparison of AI and Dermatologist Performance in Melanoma Detection

5. GENETIC MARKERS AND BIOMARKERS

1) Identification of Genetic Predisposition to Melanoma

Finding genes that make people more likely to get melanoma is now an important part of preventive cancer because it lets doctors keep an eye on people who are at a high risk and act quickly if they show any symptoms. About 5 to 10 percent of melanoma cases are thought to be passed down through families, which suggest a strong genetic link. Some important genes linked to a higher chance of melanoma are CDKN2A and CDK4, which control the cell cycle. Changes in these genes mess up the usual rules that keep cells growing, which causes cells to multiply out of control, which is a sign of cancer. As part of the screening process, people with a family history of melanoma have their DNA analysed to look for abnormalities that are known to raise the risk of getting melanoma [22].

2) Role of Biomarkers in Early Detection and Personalized Treatment Approaches

In recent years, biomarkers have become more and more important for early diagnosis and control of melanoma. They allow us to find cancer earlier and customise treatment for each patient. When it comes to melanoma, biomarkers can be proteins, gene mutations, or changes in gene expression that can be found in body fluids, blood, or tissue. For instance, the protein S100B is often high in people with melanoma and shows that the cancer is active and spreading, especially in its later stages.



Figure 4 Biomarkers in Early Detection and Personalized Treatment Approaches

Many biomarkers linked to melanoma have been found easier thanks to progress in molecular biology and bioinformatics. These signs can show if a person has melanoma, guess how well they will do with treatment, and keep an eye on how they respond. For example, BRAF mutations, which are found in about half of all melanomas, have huge effects on tailored treatment. The discovery of BRAF genes led to the creation of BRAF inhibitors, which have made things a lot better for people with advanced melanoma. Personalised treatment based on biomarker measurements is a step towards better and more accurate control of melanoma. By knowing the unique biological features of a tumour, doctors can choose treatments that are more likely to work, reducing the number of useless treatments and the harmful effects that come with them. This method not only makes medicine work better, but it also makes patients' lives better. Researchers are still looking into how to find new biomarkers using technologies like next-generation sequencing and liquid tests. This could lead to even faster discovery and better treatment plans.

3) Current Research and Future Directions in Genetic Testing for Melanoma

Genetic testing for melanoma is changing quickly because genome tools are getting better and scientists are learning more about how cancer works at the molecular level. The main goal of current study is to find more DNA markers that can tell us about melanoma risk, prognosis, and treatment reaction. Whole-genome sequencing (WGS) and whole-exome sequencing (WES) are two high-throughput sequencing methods that are being used to find new genetic variants that are linked to melanoma risk [23], [24].

6. CHALLENGES AND ETHICAL CONSIDERATIONS

1) Ethical Implications of Advanced Melanoma Detection Technologies

Using new tools to find cancer brings a lot of ethical questions, even though they could be very helpful. One big worry is the chance of overdiagnosis, which means finding moles that fit the symptoms of melanoma but won't hurt the patient during their lives. Overdiagnosis can lead to too much care, which can include surgery that isn't needed, stress, and the long-term effects of being called a cancer patient. In addition, we have a moral duty to make sure that everyone has equal access to these tools. Because of differences in healthcare, only a small part of the population may be able to benefit from improved detection tools. This could make the difference in cancer results between social classes even bigger [25]. People who use AI and other advanced technologies need to be clear about how these tools make choices, especially when those decisions affect how patients are cared for and what treatments are available.

2) Challenges in Adopting New Technologies in Clinical Settings

Putting new tools to use in professional settings can be hard for a number of reasons. The price of high-tech images and AI systems can be a big problem, especially in places with few resources [22]. Getting money for these kinds of tools could take resources away from other important healthcare services, which raises questions about how to spend money on healthcare most efficiently and what services should be prioritised. Another important problem is training. Clinicians need to be properly taught not only how to use these tools but also how to correctly analyse the results they produce. To do this, you may need to keep learning and maybe even go through licensing programs, which can take a lot of time and cost a lot of money. Another problem is getting healthcare workers and customers to use new tools. Clinicians might not trust AI's advice because they would rather use their own judgement, or they might be afraid that AI will take over their part in evaluation and treatment.

7. WEARABLE TECHNOLOGIES AND CONTINUOUS MONITORING

1) Overview of Wearable Devices for Skin Health Monitoring

A fast growing area in dermatology is wearable devices for tracking skin health. These devices are especially useful for managing and keeping an eye on skin conditions like cancer. These gadgets, which can be as simple as patches you can wear or as complex as sensors built into clothes or items you use every day, are made to constantly check different aspects of your skin.



Figure 5 Representation of Wearable Devices for Skin Health Monitoring

2) Examples of Current Technologies and Their Application in Real-Time Lesion Tracking

A number of cutting edge smart tools have been created to keep track of skin tumours really quickly. One example that stands out is a smart skin patch that has high-resolution images and analysis software that is run by AI. This patch can be put on top of a mole or other skin sore, and it will constantly track changes over time and notify users and healthcare providers of any changes that could mean the skin is cancerous. Wearables that sense UV light are another example. These devices not only keep track of how much time a person spends in the sun, but they also let the user know when they need to put on sunscreen or find shade, which helps high-risk people avoid getting cancer [24]. Bracelets and watches that use multispectral images to look at and record changes in the shape of skin tumours are another step forward. These gadgets can keep data for months or even years, which lets complex algorithms find small patterns and trends that might not be picked up by regular medical exams. By working with smartphone apps, these technologies let people keep a digital record of their skin health, which can be very helpful when they go to see a dermatologist.

8. CONCLUSION

Technology improvements and a better knowledge of how melanoma works have led to huge steps forward in finding the cancer. Dermatological detection has long used techniques like dermoscopy and total body photography. However, newer technologies like confocal microscopy, optical coherence tomography (OCT), and multispectral images are now being used to improve these methods. These more advanced imaging techniques have made it much easier to find melanoma earlier and more accurately, which could lead to better results for patients by allowing for quick and focused treatments. Adding artificial intelligence (AI) to melanoma screening is also a big step towards more standardised, reliable, and easy-to-use diagnoses. After being taught on huge collections of skin pictures, AI systems have shown that they can detect cancer as accurately as, and sometimes even more accurately than, experienced doctors. Not only does this make the testing process faster, but it also brings expert-level screening to places that don't have it yet, giving everyone access to basic medical care.

CONFLICT OF INTERESTS

None.

ACKNOWLEDGMENTS

None.

REFERENCES

Parikh, R.B.; Teeple, S.; Navathe, A.S. Addressing Bias in Artificial Intelligence in Health Care. JAMA 2019, 322, 2377–2378.

Dunn, B.K.; Woloshin, S.; Xie, H.; Kramer, B.S. Cancer overdiagnosis: A challenge in the era of screening. J. Natl. Cancer Cent. 2022, 2, 235–242.

Whiteman, D.C.; Olsen, C.M.; MacGregor, S.; Law, M.H.; Thompson, B.; Dusingize, J.C.; Green, A.C.; Neale, R.E.; Pandeya, N. The effect of screening on melanoma incidence and biopsy rates. Br. J. Dermatol. 2022, 187, 515–522.

Muzumdar, S.; Lin, G.; Kerr, P.; Grant-Kels, J.M. Evidence concerning the accusation that melanoma is overdiagnosed. J. Am. Acad. Dermatol. 2021, 85, 841–846.

Kurtansky, N.R.; Dusza, S.W.; Halpern, A.C.; Hartman, R.I.; Geller, A.C.; Marghoob, A.A.; Rotemberg, V.M.; Marchetti, M.A. An Epidemiologic Analysis of Melanoma Overdiagnosis in the United States 1975–2017. J. Investig. Dermatol. 2022, 142, 1804–1811.e6.

Garrison, Z.R.; Hall, C.M.; Fey, R.M.; Clister, T.; Khan, N.; Nichols, R.; Kulkarni, R.P. Advances in Early Detection of Melanoma and the Future of At-Home Testing. Life 2023, 13, 974.

Gosman, L.M.; Ţăpoi, D.-A.; Costache, M. Cutaneous Melanoma: A Review of Multifactorial Pathogenesis, Immunohistochemistry, and Emerging Biomarkers for Early Detection and Management. Int. J. Mol. Sci. 2023, 24, 15881.

Laskar, R.; Ferreiro-Iglesias, A.; Bishop, D.T.; Iles, M.M.; Kanetsky, P.A.; Armstrong, B.K.; Law, M.H.; Goldstein, A.M.; Aitken, J.F.; Giles, G.G.; et al. Risk factors for melanoma by anatomical site: An evaluation of aetiological heterogeneity. Br. J. Dermatol. 2021, 184, 1085–1093.

Saginala, K.; Barsouk, A.; Aluru, J.S.; Rawla, P.; Barsouk, A. Epidemiology of Melanoma. Med. Sci. 2021, 9, 63.

Zambrano-Román, M.; Padilla-Gutiérrez, J.R.; Valle, Y.; Muñoz-Valle, J.F.; Valdés-Alvarado, E. Non-Melanoma Skin Cancer: A Genetic Update and Future Perspectives. Cancers 2022, 14, 2371.

Funchain, P.; Ni, Y.; Heald, B.; Bungo, B.; Arbesman, M.; Behera, T.R.; McCormick, S.; Song, J.M.; Kennedy, L.B.; Kennedy, L.B.; et al. Germline cancer susceptibility in individuals with melanoma. J. Am. Acad. Dermatol. 2024, 91, 267.

Beigi, Y.Z.; Lanjanian, H.; Fayazi, R.; Salimi, M.; Hoseyni, B.H.M.; Noroozizadeh, M.H.; Masoudi-Nejad, A. Heterogeneity and molecular landscape of melanoma: Implications for targeted therapy. Mol. Biomed. 2024, 5, 17.

Isaak, A.J.; Clements, G.R.; Buenaventura, R.G.M.; Merlino, G.; Yu, Y. Development of Personalized Strategies for Precisely Battling Malignant Melanoma. Int. J. Mol. Sci. 2024, 25, 5023.

Tehranian, C.; Fankhauser, L.; Harter, P.N.; Ratcliffe, C.D.H.; Zeiner, P.S.; Messmer, J.M.; Hoffmann, D.C.; Frey, K.; Westphal, D.; Ronellenfitsch, M.W.; et al. The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis. Neuro Oncol. 2022, 24, 213–225.

Geng, Y.; Geng, Y.; Liu, X.; Chai, Q.; Li, X.; Ren, T.; Shang, Q. PI3K/AKT/mTOR pathway-derived risk score exhibits correlation with immune infiltration in uveal melanoma patients. Front. Oncol. 2023, 13, 1167930.

Popova, N.V.; Jücker, M. The Role of mTOR Signaling as a Therapeutic Target in Cancer. Int. J. Mol. Sci. 2021, 22, 1743.

R. Golcha, P. Khobragade and A. Talekar, "Multimodal Deep Learning for Advanced Health Monitoring A Comprehensive Approach for Enhanced Precision and Early Disease Detection," 2024 5th International Conference on Innovative Trends in Information Technology (ICITIIT), Kottayam, India, 2024, pp. 1-6, doi: 10.1109/ICITIIT61487.2024.10580622.

Peng, X.; Huang, X.; Lulu, T.B.; Jia, W.; Zhang, S.; Cohen, L.; Huang, S.; Fan, J.; Chen, X.; Liu, S.; et al. A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation. Mol. Cancer 2024, 23, 54.

Glaviano, A.; Foo, A.S.C.; Lam, H.Y.; Yap, K.C.H.; Jacot, W.; Jones, R.H.; Eng, H.; Nair, M.G.; Makvandi, P.; Geoerger, B.; et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol. Cancer 2023, 22, 138.

Lam, G.T.; Prabhakaran, S.; Sorvina, A.; Martini, C.; Ung, B.S.Y.; Karageorgos, L.; Hickey, S.M.; Lazniewska, J.; Johnson, I.R.D.; Williams, D.B.; et al. Pitfalls in cutaneous melanoma diagnosis and the need for new reliable markers. Mol. Diagn. Ther. 2023, 27, 49–60.

Gualco, M. Histopathological Examination: The Keystone of Treatment of Melanoma. In Current Management of Melanoma; Cafiero, F., De Cian, F., Eds.; Springer: Cham, Switzerland, 2021; pp. 27–37. ISBN 978-3-030-45347-3.

Proietti, I.; Skroza, N.; Michelini, S.; Mambrin, A.; Balduzzi, V.; Bernardini, N.; Marchesiello, A.; Tolino, E.; Volpe, S.; Maddalena, P.; et al. BRAF inhibitors: Molecular targeting and immunomodulatory actions. Cancers 2020, 12, 1823.

Ziogas, D.C.; Theocharopoulos, C.; Lialios, P.P.; Foteinou, D.; Koumprentziotis, I.A.; Xynos, G.; Gogas, H. Beyond CTLA-4 and PD-1 inhibition: Novel immune checkpoint molecules for melanoma treatment. Cancers 2023, 15, 2718.

Gide, T.N.; Wilmott, J.S.; Scolyer, R.A.; Long, G.V. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin. Cancer Res. 2018, 24, 1260–1270.

Prkačin, I.; Mokos, M.; Ferara, N.; Šitum, M. Melanoma's New Frontier: Exploring the Latest Advances in Blood-Based Biomarkers for Melanoma. Cancers 2024, 16, 4219